首页> 美国卫生研究院文献>American Journal of Cancer Research >MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis
【2h】

MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis

机译:MYCN介导的HES1启动子调控通过调节细胞凋亡增强小细胞肺癌的化学耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MYCN, a member of the MYC family, is correlated with tumorigenesis, metastasis and therapy in many malignancies; however, its role in small-cell lung cancer (SCLC) remains unclear. In this study, we sought to identify the function of MYCN in SCLC chemoresistance and found that MYCN is overexpressed in chemoresistant SCLC cells. We used MYCN gain- and loss-of- function experiments to demonstrate that MYCN promotes in vitro and in vivo chemoresistance in SCLC by inhibiting apoptosis. Mechanistic investigations showed that MYCN binds to the HES1 promoter and exhibits transcriptional activity. Furthermore, MYCN mediated SCLC chemoresistance through HES1. Accordingly, the NOTCH inhibitor FLI-60 derepressed HES1 and diminished MYCN-induced chemoresistance in SCLC. Finally, the positive correlation between HES1 and MYCN was confirmed in SCLC patients. Chemoresistant SCLC patients had higher expression levels of MYCN and HES1 than patients without chemoresistant SCLC. MYCN overexpression was related to advanced clinical stage and shorter survival in SCLC. In conclusion, our study revealed that MYCN and HES1 may be potential therapeutic targets and promising predictors for SCLC.
机译:MYCN是MYC家族的成员,在许多恶性肿瘤中与肿瘤发生,转移和治疗相关;然而,其在小细胞肺癌(SCLC)中的作用仍不清楚。在这项研究中,我们试图确定MYCN在SCLC化学耐药性中的功能,并发现MYCN在耐化学性SCLC细胞中过表达。我们使用MYCN功能获得和丧失功能实验来证明MYCN通过抑制细胞凋亡来促进SCLC的体外和体内化学抗性。机理研究表明,MYCN与HES1启动子结合并表现出转录活性。此外,MYCN通过HES1介导SCLC化学耐药性。因此,NOTCH抑制剂FLI-60抑制了HES1并降低了SCLC中MYCN诱导的化学耐药性。最后,在SCLC患者中证实了HES1和MYCN之间的正相关。抗化学性SCLC患者比无化学抗性SCLC的患者具有更高的MYCN和HES1表达水平。 MYCN的过表达与SCLC的晚期临床阶段和生存期短有关。总之,我们的研究表明MYCN和HES1可能是SCLC的潜在治疗靶点和有希望的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号